Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597396 · ClinicalTrials.gov registry record · Phase 2
Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID
A Phase 2 study of Fatigue Symptom and Post-COVID Condition, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT06597396: Active Phase 2 study of Fatigue Symptom and Post-COVID Condition, sponsored by Beth Israel Deaconess Medical Center.
NCT06597396 is a Phase 2 study of Fatigue Symptom and Post-COVID Condition that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 46 participants, below the 65-participant average among 3 other Fatigue Symptom trials with a reported enrollment target (29% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06597396, a Phase 2 study of Fatigue Symptom and Post-COVID Condition, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).
Primary Outcome
To compare the efficacy of abrocitinib to placebo in improving severe fatigue in adults with symptomatic PCC
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Abrocitinib
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-12-27 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What the registry record for NCT06597396 still lists
NCT06597396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 65-participant average among 3 other Fatigue Symptom trials with a reported enrollment target (29% lower).
The record links to 2 conditions, with Fatigue Symptom appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06597396 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06597396 about?
NCT06597396 is a clinical study titled "Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID". The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving ove...
What is the current status of trial NCT06597396?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2024-12-27. Estimated completion is 2026-09-30.
What conditions does trial NCT06597396 study?
This clinical trial studies the following conditions: Fatigue Symptom, Post-COVID Condition.
What interventions are being tested in trial NCT06597396?
The interventions under investigation include: Placebo (DRUG), Abrocitinib (DRUG).
Who is sponsoring clinical trial NCT06597396?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597396 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue Symptom
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI